BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that Spyros Papapetropoulos, M.D., Ph.D., President and CEO, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY. The presentation will be available on demand here starting on Friday, Se ...

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September: 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. ETMorgan Stanley 23rd Annual Global Conference on Wednesday, September 10, 2025 at ...

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate. Webinar Presentation Details:The live and archived webcast of the Company’s webinar presentation will be accessible through this webcast link, or through the E ...

Core Insights - The conference call will focus on the growing colorectal cancer crisis and emerging data from the BOT/BAL immunotherapy program [5] - The discussion will include perspectives from leading clinicians and address systemic regulatory challenges that delay access to life-extending treatments [5] Company Participants - Key executives from Agenus participating in the call include Garo H. Armen (Founder, Executive Chairman & CEO), Jennifer S. Buell (Director and President & CEO of MiNK Therapeutics), Richard M. Goldberg (Chief Development Officer), Stefanie Perna-Nacar (Chief Communications & Government Relations Officer), and Steven J. O'Day (Chief Medical Officer) [1][3] External Participants - The call will feature external thought leaders such as Dr. Nicholas DeVito (Assistant Professor of Medical Oncology, Duke University) and Dr. Chris O'Callaghan (Senior Investigator, Canadian Cancer Trials Group) [4]

Core Viewpoint - Zealand Pharma A/S will participate in several investor conferences in September 2025, showcasing its focus on innovative peptide-based medicines and providing opportunities for investor engagement [1]. Conference Participation - Zealand Pharma will attend the Jefferies Swiss Healthcare Summit on September 3, where Adam Lange will host investor meetings [2]. - The company will also be present at the Cantor Global Healthcare Conference from September 3-5, with CEO Adam Steensberg hosting meetings and participating in a fireside chat on September 4 at 8:00am EDT [3]. - At the Wells Fargo Healthcare Conference from September 3-5, Adam Steensberg will host meetings and participate in a fireside chat on September 5 at 8:45am EDT [5]. - The Morgan Stanley Annual Healthcare Conference will take place from September 8-10, with Adam Lange hosting meetings on September 10 [6]. - Zealand Pharma will participate in the Bank of America Global Healthcare Conference from September 23-25, where David Kendall will host meetings and give a presentation on September 25 at 10:45am UKT [7]. - The KBC Securities Life Sciences Conference will be held on September 25, with Adam Lange hosting meetings [8]. Company Overview - Zealand Pharma A/S is a biotechnology company focused on discovering and developing peptide-based medicines, with over 10 drug candidates in clinical development, including two that have reached the market and three in late-stage development [9]. - The company has established development and commercial partnerships with various pharmaceutical companies for its marketed products [9]. - Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma also has a presence in the U.S. [10].

These statements speak only as of the date of this presentation, and Kyverna undertakes no obligation to update or revise these statements. This presentation also contains estimates made by independent parties relating to industry market size and other data. These estimates involve a number of assumptions and limitations and you are cautioned not to give undue weight on such estimates. We have not independently verified the accuracy or completeness of such information, and we do not take any responsibility ...

Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for H1, 2025. Clinical & Development Milestones Achieved Namodenoson Drug Candidate – Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone The Phase 2a study (NCT063 ...

NEW YORK, Aug. 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY).Shareholders who purchased shares of UNCY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/unicycive-therapeutics-inc-loss-submission-form/?id=163920&from=4CLASS PERIO ...

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Wells Fargo Healthcare Conference at 3:45 p.m. ET on Thursday, September 4, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel ...

HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference taking place from September 8-10, 2025 in New York. Fireside Chat Details: ...